NX-5948
oral BTK degrader Ph. I for B-cell malignancies from degrader screening First Disclosures, ACS Fall 2023 Nurix Therapeutics, San Francisco, CA
10 minute read
Oct. 11, 2023
The Highly Potent and CNS-Active NX-5948 Shows BTK Degradation in Patients